ZA202304812B - Pharmaceutical composition for preventing or treating viral perivaginal disease - Google Patents

Pharmaceutical composition for preventing or treating viral perivaginal disease

Info

Publication number
ZA202304812B
ZA202304812B ZA2023/04812A ZA202304812A ZA202304812B ZA 202304812 B ZA202304812 B ZA 202304812B ZA 2023/04812 A ZA2023/04812 A ZA 2023/04812A ZA 202304812 A ZA202304812 A ZA 202304812A ZA 202304812 B ZA202304812 B ZA 202304812B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
vaginal
core particles
preventing
perivaginal
Prior art date
Application number
ZA2023/04812A
Other languages
English (en)
Inventor
Onogi Hiroshi
Yamaguchi Tetsuo
Sato Katsuhiko
Original Assignee
Kinopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinopharma Inc filed Critical Kinopharma Inc
Publication of ZA202304812B publication Critical patent/ZA202304812B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2023/04812A 2020-10-28 2023-04-26 Pharmaceutical composition for preventing or treating viral perivaginal disease ZA202304812B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020180339 2020-10-28
PCT/JP2021/006418 WO2022091442A1 (ja) 2020-10-28 2021-02-19 ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物

Publications (1)

Publication Number Publication Date
ZA202304812B true ZA202304812B (en) 2024-08-28

Family

ID=81382191

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/04812A ZA202304812B (en) 2020-10-28 2023-04-26 Pharmaceutical composition for preventing or treating viral perivaginal disease

Country Status (11)

Country Link
US (1) US20230398107A1 (https=)
EP (1) EP4238565B1 (https=)
JP (1) JP7606239B2 (https=)
KR (1) KR20230098175A (https=)
CN (1) CN115734782A (https=)
CA (1) CA3199945A1 (https=)
ES (1) ES3045576T3 (https=)
PL (1) PL4238565T3 (https=)
TW (1) TWI890738B (https=)
WO (1) WO2022091442A1 (https=)
ZA (1) ZA202304812B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63275519A (ja) * 1987-05-06 1988-11-14 Taisho Pharmaceut Co Ltd 難溶性薬物含有顆粒の製造方法
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2007517062A (ja) 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
JP5349309B2 (ja) * 2007-08-03 2013-11-20 株式会社キノファーマ 抗dnaウイルス作用を有するアニリン誘導体
JP2010189337A (ja) * 2009-02-19 2010-09-02 Asahi Breweries Ltd 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法
JP6138635B2 (ja) * 2013-08-30 2017-05-31 旭化成株式会社 セルロース系核粒子及びその製造方法
WO2020218518A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法
WO2020218517A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法

Also Published As

Publication number Publication date
WO2022091442A1 (ja) 2022-05-05
JP7606239B2 (ja) 2024-12-25
KR20230098175A (ko) 2023-07-03
EP4238565C0 (en) 2025-09-24
PL4238565T3 (pl) 2025-12-22
ES3045576T3 (en) 2025-11-28
EP4238565A4 (en) 2024-10-09
CA3199945A1 (en) 2022-05-05
EP4238565A1 (en) 2023-09-06
JPWO2022091442A1 (https=) 2022-05-05
EP4238565B1 (en) 2025-09-24
TW202216142A (zh) 2022-05-01
TWI890738B (zh) 2025-07-21
US20230398107A1 (en) 2023-12-14
CN115734782A (zh) 2023-03-03

Similar Documents

Publication Publication Date Title
MX2023013892A (es) Analogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn).
JP5860197B1 (ja) ウイルス感染症を処置するための治療用化合物
KR101235102B1 (ko) 플리반세린을 포함하는 성욕 장애 치료용 약제학적 조성물
MY202837A (en) Lipids for lipid nanoparticle delivery of active agents
TW202019900A (zh) Ptpn11抑制劑
JP5192517B2 (ja) 治療又は予防薬
HRP20100180T1 (hr) Novi spoj piridazina i njegova primjena
MXPA04000905A (es) Derivados de amino-ftalazinona activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CN102532133A (zh) 适用作詹纳斯激酶抑制剂的吖吲哚类
EA200970535A1 (ru) Антибактериальные производные хинолина
RU2014105577A (ru) Капсулированная лекарственная форма, содержащая монтелукаст и левоцетиризин
US10945996B2 (en) Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
WO2012058378A1 (en) Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
CA2645211A1 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
SI2800558T1 (en) A stable pharmaceutical formulation for oral administration comprising levocetirizines or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
EA200970534A1 (ru) Антибактериальные производные хинолина
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
ZA202304812B (en) Pharmaceutical composition for preventing or treating viral perivaginal disease
MX2023001725A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos.
BR0210191A (pt) Agentes não peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso, e processos para os preparar e aos seus intermediários
PH12020552236A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
ZA202108670B (en) Pharmaceutical preparation and method for producing same
US20080161249A1 (en) Use of Novel Antibacterial Compounds